Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
40.99
+0.04 (0.10%)
At close: Apr 28, 2026, 4:00 PM EDT
40.99
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:38 PM EDT
Apellis Pharmaceuticals Employees
As of December 31, 2025, Apellis Pharmaceuticals had 739 total employees, including 733 full-time and 6 part-time employees. The number of employees increased by 29 or 4.08% compared to the previous year.
Employees
739
Change (1Y)
29
Growth (1Y)
4.08%
Revenue / Employee
$1,358,298
Profits / Employee
$30,295
Market Cap
5.25B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,846 |
| PTC Therapeutics | 991 |
| Corcept Therapeutics | 730 |
| TG Therapeutics | 399 |
| CRISPR Therapeutics AG | 393 |
| Mirum Pharmaceuticals | 372 |
| Xenon Pharmaceuticals | 370 |
| Immunovant | 362 |
APLS News
- 4 weeks ago - Why This Pharma Stock More Than Doubled Today - Barrons
- 4 weeks ago - Biogen will acquire a drug company for $5.6 billion to expand work in kidney diseases - Market Watch
- 4 weeks ago - Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion - WSJ
- 4 weeks ago - Biogen to buy Apellis Pharmaceuticals for $5.6 billion - Reuters
- 4 weeks ago - Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology. - GlobeNewsWire
- 4 weeks ago - Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology - GlobeNewsWire
- 2 months ago - Apellis Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors - GlobeNewsWire